1 Overactive Bladder (OAB) Therapeutics Market Overview 1.1 Overactive Bladder (OAB) Therapeutics Product Overview 1.2 Overactive Bladder (OAB) Therapeutics Market Segment by Type 1.2.1 Anticholinergic Agents 1.2.2 Beta-3 Adrenoreceptor Agonists 1.3 Global Overactive Bladder (OAB) Therapeutics Market Size by Type (2015-2026) 1.3.1 Global Overactive Bladder (OAB) Therapeutics Market Size Overview by Type (2015-2026) 1.3.2 Global Overactive Bladder (OAB) Therapeutics Historic Market Size Review by Type (2015-2020) 1.3.2.1 Global Overactive Bladder (OAB) Therapeutics Sales Market Share Breakdown by Type (2015-2026) 1.3.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share Breakdown by Type (2015-2026) 1.3.2.3 Global Overactive Bladder (OAB) Therapeutics Average Selling Price (ASP) by Type (2015-2026) 1.3.3 Global Overactive Bladder (OAB) Therapeutics Market Size Forecast by Type (2021-2026) 1.3.3.1 Global Overactive Bladder (OAB) Therapeutics Sales Market Share Breakdown by Application (2021-2026) 1.3.3.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share Breakdown by Application (2021-2026) 1.3.3.3 Global Overactive Bladder (OAB) Therapeutics Average Selling Price (ASP) by Application (2021-2026) 1.4 Key Regions Market Size Segment by Type (2015-2020) 1.4.1 North America Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2015-2026) 1.4.2 Europe Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2015-2026) 1.4.3 Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2015-2026) 1.4.4 Latin America Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2015-2026) 1.4.5 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2015-2026) 2 Global Overactive Bladder (OAB) Therapeutics Market Competition by Company 2.1 Global Top Players by Overactive Bladder (OAB) Therapeutics Sales (2015-2020) 2.2 Global Top Players by Overactive Bladder (OAB) Therapeutics Revenue (2015-2020) 2.3 Global Top Players Overactive Bladder (OAB) Therapeutics Average Selling Price (ASP) (2015-2020) 2.4 Global Top Manufacturers Overactive Bladder (OAB) Therapeutics Manufacturing Base Distribution, Sales Area, Product Type 2.5 Overactive Bladder (OAB) Therapeutics Market Competitive Situation and Trends 2.5.1 Overactive Bladder (OAB) Therapeutics Market Concentration Rate (2015-2020) 2.5.2 Global 5 and 10 Largest Manufacturers by Overactive Bladder (OAB) Therapeutics Sales and Revenue in 2019 2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Overactive Bladder (OAB) Therapeutics as of 2019) 2.7 Date of Key Manufacturers Enter into Overactive Bladder (OAB) Therapeutics Market 2.8 Key Manufacturers Overactive Bladder (OAB) Therapeutics Product Offered 2.9 Mergers & Acquisitions, Expansion 3 Global Overactive Bladder (OAB) Therapeutics Status and Outlook by Region (2015-2026) 3.1 Global Overactive Bladder (OAB) Therapeutics Market Size and CAGR by Region: 2015 VS 2020 VS 2026 3.2 Global Overactive Bladder (OAB) Therapeutics Market Size Market Share by Region (2015-2020) 3.2.1 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2015-2020) 3.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2015-2020) 3.2.3 Global Overactive Bladder (OAB) Therapeutics Sales, Revenue, Price and Gross Margin (2015-2020) 3.3 Global Overactive Bladder (OAB) Therapeutics Market Size Market Share by Region (2021-2026) 3.3.1 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2021-2026) 3.3.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2021-2026) 3.3.3 Global Overactive Bladder (OAB) Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026) 3.4 North America Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 3.4.1 North America Overactive Bladder (OAB) Therapeutics Revenue YoY Growth (2015-2026) 3.4.2 North America Overactive Bladder (OAB) Therapeutics Sales YoY Growth (2015-2026) 3.5 Asia-Pacific Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 3.5.1 Asia-Pacific Overactive Bladder (OAB) Therapeutics Revenue YoY Growth (2015-2026) 3.5.2 Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales YoY Growth (2015-2026) 3.6 Europe Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 3.6.1 Europe Overactive Bladder (OAB) Therapeutics Revenue YoY Growth (2015-2026) 3.6.2 Europe Overactive Bladder (OAB) Therapeutics Sales YoY Growth (2015-2026) 3.7 Latin America Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 3.7.1 Latin America Overactive Bladder (OAB) Therapeutics Revenue YoY Growth (2015-2026) 3.7.2 Latin America Overactive Bladder (OAB) Therapeutics Sales YoY Growth (2015-2026) 3.8 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 3.8.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue YoY Growth (2015-2026) 3.8.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales YoY Growth (2015-2026) 4 Global Overactive Bladder (OAB) Therapeutics by Application 4.1 Overactive Bladder (OAB) Therapeutics Segment by Application 4.1.1 Hosptial 4.1.2 Clinci 4.1.3 Other 4.2 Global Overactive Bladder (OAB) Therapeutics Sales by Application: 2015 VS 2020 VS 2026 4.3 Global Overactive Bladder (OAB) Therapeutics Historic Sales by Application (2015-2020) 4.4 Global Overactive Bladder (OAB) Therapeutics Forecasted Sales by Application (2021-2026) 4.5 Key Regions Overactive Bladder (OAB) Therapeutics Market Size by Application 4.5.1 North America Overactive Bladder (OAB) Therapeutics by Application 4.5.2 Europe Overactive Bladder (OAB) Therapeutics by Application 4.5.3 Asia-Pacific Overactive Bladder (OAB) Therapeutics by Application 4.5.4 Latin America Overactive Bladder (OAB) Therapeutics by Application 4.5.5 Middle East and Africa Overactive Bladder (OAB) Therapeutics by Application 5 North America Overactive Bladder (OAB) Therapeutics Market Size by Country (2015-2026) 5.1 North America Market Size Market Share by Country (2015-2020) 5.1.1 North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2015-2020) 5.1.2 North America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2015-2020) 5.2 North America Market Size Market Share by Country (2021-2026) 5.2.1 North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2021-2026) 5.2.2 North America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2021-2026) 5.3 North America Market Size YoY Growth by Country 5.3.1 U.S. Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 5.3.2 Canada Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 6 Europe Overactive Bladder (OAB) Therapeutics Market Size by Country (2015-2026) 6.1 Europe Market Size Market Share by Country (2015-2020) 6.1.1 Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2015-2020) 6.1.2 Europe Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2015-2020) 6.2 Europe Market Size Market Share by Country (2021-2026) 6.2.1 Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2021-2026) 6.2.2 Europe Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2021-2026) 6.3 Europe Market Size YoY Growth by Country 6.3.1 Germany Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 6.3.2 France Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 6.3.3 U.K. Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 6.3.4 Italy Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 6.3.5 Russia Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 7 Asia-Pacific Overactive Bladder (OAB) Therapeutics Market Size by Country (2015-2026) 7.1 Asia-Pacific Market Size Market Share by Country (2015-2020) 7.1.1 Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2015-2020) 7.1.2 Asia-Pacific Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2015-2020) 7.2 Asia-Pacific Market Size Market Share by Country (2021-2026) 7.2.1 Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2021-2026) 7.2.2 Asia-Pacific Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2021-2026) 7.3 Asia-Pacific Market Size YoY Growth by Country 7.3.1 China Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 7.3.2 Japan Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 7.3.3 South Korea Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 7.3.4 India Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 7.3.5 Australia Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 7.3.6 Taiwan Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 7.3.7 Indonesia Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 7.3.8 Thailand Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 7.3.9 Malaysia Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 7.3.10 Philippines Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 7.3.11 Vietnam Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 8 Latin America Overactive Bladder (OAB) Therapeutics Market Size by Country (2015-2026) 8.1 Latin America Market Size Market Share by Country (2015-2020) 8.1.1 Latin America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2015-2020) 8.1.2 Latin America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2015-2020) 8.2 Latin America Market Size Market Share by Country (2021-2026) 8.2.1 Latin America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2021-2026) 8.2.2 Latin America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2021-2026) 8.3 Latin America Market Size YoY Growth by Country 8.3.1 Mexico Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 8.3.2 Brazil Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 8.3.3 Argentina Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 9 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Size by Country (2015-2026) 9.1 Middle East and Africa Market Size Market Share by Country (2015-2020) 9.1.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2015-2020) 9.1.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2015-2020) 9.2 Middle East and Africa Market Size Market Share by Country (2021-2026) 9.2.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2021-2026) 9.2.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2021-2026) 9.3 Middle East and Africa Market Size YoY Growth by Country 9.3.1 Turkey Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 9.3.2 Saudi Arabia Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 9.3.3 U.A.E Overactive Bladder (OAB) Therapeutics Market Size YoY Growth (2015-2026) 10 Company Profiles and Key Figures in Overactive Bladder (OAB) Therapeutics Business 10.1 Allergan 10.1.1 Allergan Corporation Information 10.1.2 Allergan Description, Business Overview and Total Revenue 10.1.3 Allergan Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2015-2020) 10.1.4 Allergan Overactive Bladder (OAB) Therapeutics Products Offered 10.1.5 Allergan Recent Development 10.2 Astellas Pharma 10.2.1 Astellas Pharma Corporation Information 10.2.2 Astellas Pharma Description, Business Overview and Total Revenue 10.2.3 Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2015-2020) 10.2.4 Allergan Overactive Bladder (OAB) Therapeutics Products Offered 10.2.5 Astellas Pharma Recent Development 10.3 Hisamitsu Pharmaceutical 10.3.1 Hisamitsu Pharmaceutical Corporation Information 10.3.2 Hisamitsu Pharmaceutical Description, Business Overview and Total Revenue 10.3.3 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2015-2020) 10.3.4 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Products Offered 10.3.5 Hisamitsu Pharmaceutical Recent Development 10.4 Pfizer 10.4.1 Pfizer Corporation Information 10.4.2 Pfizer Description, Business Overview and Total Revenue 10.4.3 Pfizer Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2015-2020) 10.4.4 Pfizer Overactive Bladder (OAB) Therapeutics Products Offered 10.4.5 Pfizer Recent Development 10.5 Ferring 10.5.1 Ferring Corporation Information 10.5.2 Ferring Description, Business Overview and Total Revenue 10.5.3 Ferring Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2015-2020) 10.5.4 Ferring Overactive Bladder (OAB) Therapeutics Products Offered 10.5.5 Ferring Recent Development 10.6 GlaxoSmithKline 10.6.1 GlaxoSmithKline Corporation Information 10.6.2 GlaxoSmithKline Description, Business Overview and Total Revenue 10.6.3 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2015-2020) 10.6.4 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Products Offered 10.6.5 GlaxoSmithKline Recent Development 10.7 Ion Channel Innovations 10.7.1 Ion Channel Innovations Corporation Information 10.7.2 Ion Channel Innovations Description, Business Overview and Total Revenue 10.7.3 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2015-2020) 10.7.4 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Products Offered 10.7.5 Ion Channel Innovations Recent Development 10.8 Kwang Dong Pharmaceutical 10.8.1 Kwang Dong Pharmaceutical Corporation Information 10.8.2 Kwang Dong Pharmaceutical Description, Business Overview and Total Revenue 10.8.3 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2015-2020) 10.8.4 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Products Offered 10.8.5 Kwang Dong Pharmaceutical Recent Development 10.9 Lanzhou Institute of Biological Products 10.9.1 Lanzhou Institute of Biological Products Corporation Information 10.9.2 Lanzhou Institute of Biological Products Description, Business Overview and Total Revenue 10.9.3 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2015-2020) 10.9.4 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Products Offered 10.9.5 Lanzhou Institute of Biological Products Recent Development 10.10 Merck 10.10.1 Company Basic Information, Manufacturing Base and Competitors 10.10.2 Overactive Bladder (OAB) Therapeutics Product Category, Application and Specification 10.10.3 Merck Overactive Bladder (OAB) Therapeutics Sales, Revenue, Price and Gross Margin (2015-2020) 10.10.4 Main Business Overview 10.10.5 Merck Recent Development 10.11 ONO Pharmaceutical 10.11.1 ONO Pharmaceutical Corporation Information 10.11.2 ONO Pharmaceutical Description, Business Overview and Total Revenue 10.11.3 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2015-2020) 10.11.4 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Products Offered 10.11.5 ONO Pharmaceutical Recent Development 10.12 Sanofi 10.12.1 Sanofi Corporation Information 10.12.2 Sanofi Description, Business Overview and Total Revenue 10.12.3 Sanofi Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2015-2020) 10.12.4 Sanofi Overactive Bladder (OAB) Therapeutics Products Offered 10.12.5 Sanofi Recent Development 10.13 Tengion 10.13.1 Tengion Corporation Information 10.13.2 Tengion Description, Business Overview and Total Revenue 10.13.3 Tengion Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2015-2020) 10.13.4 Tengion Overactive Bladder (OAB) Therapeutics Products Offered 10.13.5 Tengion Recent Development 10.14 Teva Pharmaceutical Industries 10.14.1 Teva Pharmaceutical Industries Corporation Information 10.14.2 Teva Pharmaceutical Industries Description, Business Overview and Total Revenue 10.14.3 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2015-2020) 10.14.4 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Products Offered 10.14.5 Teva Pharmaceutical Industries Recent Development 11 Overactive Bladder (OAB) Therapeutics Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis 11.1 Overactive Bladder (OAB) Therapeutics Key Raw Materials 11.1.1 Key Raw Materials 11.1.2 Key Raw Materials Price 11.1.3 Raw Materials Key Suppliers 11.2 Manufacturing Cost Structure 11.2.1 Raw Materials 11.2.2 Labor Cost 11.2.3 Manufacturing Expenses 11.3 Overactive Bladder (OAB) Therapeutics Industrial Chain Analysis 11.4 Market Opportunities, Challenges, Risks and Influences Factors Analysis 11.4.1 Industry Trends 11.4.2 Market Drivers 11.4.3 Market Challenges 11.4.4 Porter’s Five Forces Analysis 12 Market Strategy Analysis, Distributors 12.1 Sales Channel 12.2 Distributors 12.3 Downstream Customers 13 Research Findings and Conclusion 14 Appendix 14.1 Methodology/Research Approach 14.1.1 Research Programs/Design 14.1.2 Market Size Estimation 14.1.3 Market Breakdown and Data Triangulation 14.2 Data Source 14.2.1 Secondary Sources 14.2.2 Primary Sources 14.3 Author Details 14.4 Disclaimer

List of Tables Table 1. Major Players of Anticholinergic Agents Table 2. Major Players of Beta-3 Adrenoreceptor Agonists Table 3. Global Overactive Bladder (OAB) Therapeutics Market Size Growth Potential by Type: CAGR (2020-2026) (US$ Million) Table 4. Global Overactive Bladder (OAB) Therapeutics Sales (MT) by Type (2015-2020) (MT) Table 5. Global Overactive Bladder (OAB) Therapeutics Sales Share by Type (2015-2020) Table 6. Global Overactive Bladder (OAB) Therapeutics Revenue (Million USD) by Type (2015-2020) Table 7. Global Overactive Bladder (OAB) Therapeutics Revenue Share by Type (2015-2020) Table 8. Global Overactive Bladder (OAB) Therapeutics Average Selling Price (ASP) (USD/Kg) by Type (2015-2020) Table 9. Global Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2026) (MT) Table 10. Global Overactive Bladder (OAB) Therapeutics Sales Share by Type (2021-2026) Table 11. Global Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Type (2021-2026) Table 12. Global Overactive Bladder (OAB) Therapeutics Revenue Share by Type (2021-2026) Table 13. Global Overactive Bladder (OAB) Therapeutics Average Selling Price (ASP) (USD/Kg) by Type (2021-2026) Table 14. North America Overactive Bladder (OAB) Therapeutics Sales (USD/Kg) by Type (2015-2020) Table 15. Europe Overactive Bladder (OAB) Therapeutics Sales (USD/Kg) by Type (2015-2020) Table 16. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales (USD/Kg) by Type (2015-2020) Table 17. Latin America Overactive Bladder (OAB) Therapeutics Sales (USD/Kg) by Type (2015-2020) Table 18. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales (USD/Kg) by Type (2015-2020) Table 19. Global Overactive Bladder (OAB) Therapeutics Sales (MT) by Company (2015-2020) Table 20. Global Overactive Bladder (OAB) Therapeutics Sales Share by Company (2015-2020) Table 21. Global Overactive Bladder (OAB) Therapeutics Revenue (Million US$) by Company (2015-2020) Table 22. Global Overactive Bladder (OAB) Therapeutics Revenue Share by Company (2015-2020) Table 23. Global Market Overactive Bladder (OAB) Therapeutics Average Selling Price (USD/Kg) by Company (2015-2020) Table 24. Global Overactive Bladder (OAB) Therapeutics Top Manufacturers Manufacturing Base Distribution and Sales Area Table 25. Global Overactive Bladder (OAB) Therapeutics Top Manufacturers Product Category Table 26. Global Overactive Bladder (OAB) Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI) Table 27. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Overactive Bladder (OAB) Therapeutics as of 2019 Table 28. Date of Key Manufacturers Enter into Overactive Bladder (OAB) Therapeutics Market Table 29. Key Manufacturers Overactive Bladder (OAB) Therapeutics Product Type Table 30. Mergers & Acquisitions, Expansion Plans Table 31. Global Overactive Bladder (OAB) Therapeutics Market Size Comparison by Region (2015-2026) (US$ Million): 2015 VS 2020 VS 2026 Table 32. Global Overactive Bladder (OAB) Therapeutics Sales (MT) by Region (2015-2020) Table 33. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2015-2020) Table 34. Global Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Region (2015-2020) Table 35. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2015-2020) Table 36. Global Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020) Table 37. Global Overactive Bladder (OAB) Therapeutics Sales (MT) by Region (2021-2026) Table 38. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2021-2026) Table 39. Global Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Region (2021-2026) Table 40. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2021-2026) Table 41. Global Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 42. Global Overactive Bladder (OAB) Therapeutics Sales (MT) by Application: 2015 VS 2020 VS 2026 Table 43. Global Overactive Bladder (OAB) Therapeutics Sales (MT) by Application (2015-2020) Table 44. Global Overactive Bladder (OAB) Therapeutics Sales Share by Application (2015-2020) Table 45. Global Overactive Bladder (OAB) Therapeutics Sales (MT) by Application (2021-2026) Table 46. Global Overactive Bladder (OAB) Therapeutics Sales Share by Application (2021-2026) Table 47. North America Overactive Bladder (OAB) Therapeutics Sales (MT) by Application (2015-2020) Table 48. North America Sales Overactive Bladder (OAB) Therapeutics Market Share by Application (2015-2020) Table 49. Europe Overactive Bladder (OAB) Therapeutics Sales (MT) by Application (2015-2020) Table 50. Europe Sales Overactive Bladder (OAB) Therapeutics Market Share by Application In 2019 Table 51. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales (MT) by Application (2015-2020) Table 52. Asia-Pacific Sales Overactive Bladder (OAB) Therapeutics Market Share by Application In 2019 Table 53. Latin America Overactive Bladder (OAB) Therapeutics Sales (MT) by Application (2015-2020) Table 54. Latin America Sales Overactive Bladder (OAB) Therapeutics Market Share by Application In 2019 Table 55. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales (MT) by Application (2015-2020) Table 56. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Share by Application (2015-2020) Table 57. North America Overactive Bladder (OAB) Therapeutics Sales (MT) by Country (2015-2020) Table 58. North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2015-2020) Table 59. North America Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Country (2015-2020) Table 60. North America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2015-2020) Table 61. North America Overactive Bladder (OAB) Therapeutics Sales (MT) by Country (2021-2026) Table 62. North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2021-2026) Table 63. North America Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Country (2021-2026) Table 64. North America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2021-2026) Table 65. Europe Overactive Bladder (OAB) Therapeutics Sales (MT) by Country (2015-2020) Table 66. Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2015-2020) Table 67. Europe Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Country (2015-2020) Table 68. Europe Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2015-2020) Table 69. Europe Overactive Bladder (OAB) Therapeutics Sales (MT) by Country (2021-2026) Table 70. Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2021-2026) Table 71. Europe Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Country (2021-2026) Table 72. Europe Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2021-2026) Table 73. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales (MT) by Region (2015-2020) Table 74. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2015-2020) Table 75. Asia-Pacific Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Region (2015-2020) Table 76. Asia-Pacific Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2015-2020) Table 77. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales (MT) by Region (2021-2026) Table 78. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2021-2026) Table 79. Asia-Pacific Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Region (2021-2026) Table 80. Asia-Pacific Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2021-2026) Table 81. Latin America Overactive Bladder (OAB) Therapeutics Sales (MT) by Country (2015-2020) Table 82. Latin America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2015-2020) Table 83. Latin America Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Country (2015-2020) Table 84. Latin America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2015-2020) Table 85. Latin America Overactive Bladder (OAB) Therapeutics Sales (MT) by Country (2021-2026) Table 86. Latin America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2021-2026) Table 87. Latin America Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Country (2021-2026) Table 88. Latin America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2021-2026) Table 89. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales (MT) by Country (2015-2020) Table 90. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2015-2020) Table 91. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Country (2015-2020) Table 92. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2015-2020) Table 93. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales (MT) by Country (2021-2026) Table 94. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2021-2026) Table 95. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Country (2021-2026) Table 96. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2021-2026) Table 97. Allergan Corporation Information Table 98. Allergan Description and Business Overview Table 99. Allergan Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020) Table 100. Allergan Overactive Bladder (OAB) Therapeutics Product Table 101. Allergan Recent Development Table 102. Astellas Pharma Corporation Information Table 103. Astellas Pharma Description and Business Overview Table 104. Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020) Table 105. Astellas Pharma Overactive Bladder (OAB) Therapeutics Product Table 106. Astellas Pharma Recent Development Table 107. Hisamitsu Pharmaceutical Corporation Information Table 108. Hisamitsu Pharmaceutical Description and Business Overview Table 109. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020) Table 110. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Table 111. Hisamitsu Pharmaceutical Recent Development Table 112. Pfizer Corporation Information Table 113. Pfizer Description and Business Overview Table 114. Pfizer Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020) Table 115. Pfizer Overactive Bladder (OAB) Therapeutics Product Table 116. Pfizer Recent Development Table 117. Ferring Corporation Information Table 118. Ferring Description and Business Overview Table 119. Ferring Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020) Table 120. Ferring Overactive Bladder (OAB) Therapeutics Product Table 121. Ferring Recent Development Table 122. GlaxoSmithKline Corporation Information Table 123. GlaxoSmithKline Description and Business Overview Table 124. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020) Table 125. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product Table 126. GlaxoSmithKline Recent Development Table 127. Ion Channel Innovations Corporation Information Table 128. Ion Channel Innovations Description and Business Overview Table 129. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020) Table 130. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product Table 131. Ion Channel Innovations Recent Development Table 132. Kwang Dong Pharmaceutical Corporation Information Table 133. Kwang Dong Pharmaceutical Description and Business Overview Table 134. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020) Table 135. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Table 136. Kwang Dong Pharmaceutical Recent Development Table 137. Lanzhou Institute of Biological Products Corporation Information Table 138. Lanzhou Institute of Biological Products Description and Business Overview Table 139. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020) Table 140. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product Table 141. Lanzhou Institute of Biological Products Recent Development Table 142. Merck Corporation Information Table 143. Merck Description and Business Overview Table 144. Merck Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020) Table 145. Merck Overactive Bladder (OAB) Therapeutics Product Table 146. Merck Recent Development Table 147. ONO Pharmaceutical Corporation Information Table 148. ONO Pharmaceutical Description and Business Overview Table 149. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020) Table 150. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Table 151. ONO Pharmaceutical Recent Development Table 152. Sanofi Corporation Information Table 153. Sanofi Description and Business Overview Table 154. Sanofi Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020) Table 155. Sanofi Overactive Bladder (OAB) Therapeutics Product Table 156. Sanofi Recent Development Table 157. Tengion Corporation Information Table 158. Tengion Description and Business Overview Table 159. Tengion Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020) Table 160. Tengion Overactive Bladder (OAB) Therapeutics Product Table 161. Tengion Recent Development Table 162. Teva Pharmaceutical Industries Corporation Information Table 163. Teva Pharmaceutical Industries Description and Business Overview Table 164. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2015-2020) Table 165. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product Table 166. Teva Pharmaceutical Industries Recent Development Table 167. Key Raw Materials Lists Table 168. Raw Materials Key Suppliers Lists Table 169. Key Opportunities and Drivers: Impact Analysis (2021-2026) Table 170. Key Challenges Table 171. Market Risks Table 172. Distributors List Table 173. Overactive Bladder (OAB) Therapeutics Downstream Customers Table 174. Research Programs/Design for This Report Table 175. Key Data Information from Secondary Sources Table 176. Key Data Information from Primary Sources List of Figures Figure 1. Overactive Bladder (OAB) Therapeutics Product Picture Figure 2. Global Overactive Bladder (OAB) Therapeutics Revenue (Million USD) Status and Outlook (2015-2026) Figure 3. Global Overactive Bladder (OAB) Therapeutics Sales (MT) Status and Outlook (2015-2026) Figure 4. Product Picture of Anticholinergic Agents Figure 5. Global Anticholinergic Agents Sales (MT) and Growth Rate (2015-2020) Figure 6. Product Picture of Beta-3 Adrenoreceptor Agonists Figure 7. Global Beta-3 Adrenoreceptor Agonists Sales (MT) and Growth Rate (2015-2020) Figure 8. Global Overactive Bladder (OAB) Therapeutics Revenue and Growth Rate by Type (US$ Million) Figure 9. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2015-2020) Figure 10. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type in 2019 Figure 11. Global Overactive Bladder (OAB) Therapeutics Revenue Share by Type (2015-2020) Figure 12. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type in 2019 Figure 13. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2021-2026) Figure 14. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type In 2019 Figure 15. Global Overactive Bladder (OAB) Therapeutics Revenue Share by Type (2021-2026) Figure 16. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type In 2019 Figure 17. The 5 and 10 Largest Manufacturers in the World: Market Share by Overactive Bladder (OAB) Therapeutics Sales in 2019 Figure 18. The 5 and 10 Largest Manufacturers in the World: Market Share by Overactive Bladder (OAB) Therapeutics Revenue in 2019 Figure 19. Overactive Bladder (OAB) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019 Figure 20. North America Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) and Growth Rate (2015-2026) Figure 21. North America Overactive Bladder (OAB) Therapeutics Sales YoY Growth (2015-2026) (MT) Figure 22. Asia-Pacific Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) and Growth Rate (2015-2026) Figure 23. Asia-Pacific Overactive Bladder (OAB) Therapeutics Sales YoY Growth (2015-2026) (MT) Figure 24. Europe Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) and Growth Rate (2015-2026) Figure 25. Europe Overactive Bladder (OAB) Therapeutics Sales YoY Growth (2015-2026) (MT) Figure 26. Latin America Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) and Growth Rate (2015-2026) Figure 27. Latin America Overactive Bladder (OAB) Therapeutics Sales YoY Growth (2015-2026) (MT) Figure 28. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) and Growth Rate (2015-2026) Figure 29. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales YoY Growth (2015-2026) (MT) Figure 30. Hosptial Examples Figure 31. Clinci Examples Figure 32. Other Examples Figure 33. U.S. Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 34. U.S. Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 35. Canada Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 36. Canada Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 37. Germany Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 38. Germany Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 39. France Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 40. France Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 41. U.K. Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 42. U.K. Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 43. Italy Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 44. Italy Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 45. Russia Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 46. Russia Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 47. China Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 48. China Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 49. Japan Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 50. Japan Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 51. South Korea Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 52. South Korea Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 53. India Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 54. India Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 55. Australia Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 56. Australia Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 57. Taiwan Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 58. Taiwan Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 59. Indonesia Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 60. Indonesia Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 61. Thailand Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 62. Thailand Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 63. Malaysia Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 64. Malaysia Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 65. Philippines Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 66. Philippines Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 67. Vietnam Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 68. Vietnam Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 69. Mexico Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 70. Mexico Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 71. Brazil Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 72. Brazil Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 73. Argentina Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 74. Argentina Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 75. Turkey Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 76. Turkey Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 77. Saudi Arabia Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 78. Saudi Arabia Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 79. U.A.E Overactive Bladder (OAB) Therapeutics Sales (MT) (2015-2026) Figure 80. U.A.E Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) (2015-2026) Figure 81. Allergan Total Revenue (US$ Million): 2019 Compared with 2018 Figure 82. Astellas Pharma Total Revenue (US$ Million): 2019 Compared with 2018 Figure 83. Hisamitsu Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018 Figure 84. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018 Figure 85. Ferring Total Revenue (US$ Million): 2019 Compared with 2018 Figure 86. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018 Figure 87. Ion Channel Innovations Total Revenue (US$ Million): 2019 Compared with 2018 Figure 88. Kwang Dong Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018 Figure 89. Lanzhou Institute of Biological Products Total Revenue (US$ Million): 2019 Compared with 2018 Figure 90. Merck Total Revenue (US$ Million): 2019 Compared with 2018 Figure 91. ONO Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018 Figure 92. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018 Figure 93. Tengion Total Revenue (US$ Million): 2019 Compared with 2018 Figure 94. Teva Pharmaceutical Industries Total Revenue (US$ Million): 2019 Compared with 2018 Figure 95. Key Raw Materials Price Figure 96. Overactive Bladder (OAB) Therapeutics Manufacturing Cost Structure Figure 97. Overactive Bladder (OAB) Therapeutics Industrial Chain Analysis Figure 98. Porter's Five Forces Analysis Figure 99. Channels of Distribution Figure 100. Distributors Profiles Figure 101. Bottom-up and Top-down Approaches for This Report Figure 102. Data Triangulation Figure 103. Key Executives Interviewed

Allergan Astellas Pharma Hisamitsu Pharmaceutical Pfizer Ferring GlaxoSmithKline Ion Channel Innovations Kwang Dong Pharmaceutical Lanzhou Institute of Biological Products Merck ONO Pharmaceutical Sanofi Tengion Teva Pharmaceutical Industries